ストックスクリーナーアプリを入手
35.89
0.69%
-0.25
前日終値:
$36.14
開ける：
$36.4
24時間の取引高:
481.82K
Relative Volume:
1.11
時価総額：
$1.32B
収益：
$154.15M
当期純損益:
$-33.58M
株価収益率:
-37.39
EPS:
-0.96
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
+2.75%
1か月 パフォーマンス:
+13.86%
6か月 パフォーマンス:
+6.03%
1年 パフォーマンス:
+45.95%
1日の値動き範囲:
$35.60
$36.93
1週間の範囲:
$33.33
$37.27
52週間の値動き範囲:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
HROW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
35.89 | 1.28B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
148.60 | 68.99B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 46.36B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.60 | 44.74B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.06 | 18.81B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.01 | 13.33B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | BTIG Research | Buy |
| 2025-06-10 | 開始されました | William Blair | Outperform |
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
What drives Harrow Inc. stock pricePhenomenal capital appreciation - Jammu Links News
Harrow Inc. Stock Analysis and ForecastFree Investment Case Studies - PrintWeekIndia
Is Harrow Inc. a good long term investmentOutstanding capital appreciation - Jammu Links News
What analysts say about Harrow Inc. stockAccelerated profit realization - Jammu Links News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - WV News
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Cantor Fitzgerald Initiates Harrow at Overweight With $76 Price Target - MarketScreener
Betting on Ophthalmic Growth Amid Strong Analyst Backing: Harrow, Inc.'s Strategic Play - AInvest
Harrow: Immense Upside Potential (NASDAQ:HROW) - Seeking Alpha
Ongoing Securities Investigation into Harrow, Inc. (HROW)Contact Levi & Korsinsky - ACCESS Newswire
HROW Investor Notice: Levi & Korsinsky Investigates Harrow, Inc. for Securities Law Violations - ACCESS Newswire
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harrow, Inc. (HROW) And Encourages Stockholders to Reach Out - ACCESS Newswire
Harrow, Inc. Fraud Investigation: A Litigation-Driven Opportunity for Shareholder Recovery - AInvest
13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey
Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN
Are Options Traders Betting on a Big Move in Harrow Stock? - TradingView
HROW to Participate in Lake Street's Virtual Meeting on June 24 - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications | HROW Stock News - GuruFocus
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications - Business Wire
Opaleye Management Inc. Adjusts Holdings in Harrow Inc. - GuruFocus
Institutional Investors Control 46% of Harrow, Inc. (NASDAQ:HROW) and Were Rewarded Last Week After Stock Increased 4.6% - 富途牛牛
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
4.65%
大文字化:
|
ボリューム (24 時間):